
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
Connect with pharmaceutical and healthcare regulatory authorities around the world via this directory.
over 5 years ago
It Takes a Bio/Pharma Villageover 5 years ago
Managing the Risk of Nitrosamine Impuritiesover 5 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 5 years ago
Can FDA Reinvent Inspectionsover 5 years ago
FDA 2021 Guidance Agenda Sees Focus on Genericsover 5 years ago
A Real-World Approach to Evaluating Cleanroom Garmentsover 5 years ago
Resources, Guidelines, and Guidance Documents Directory




